可孚醫療(301087.SZ)：擬以5027萬元收購吉芮醫療54.0539%股權
格隆匯11月7日丨可孚醫療(301087.SZ)公佈，公司擬與轉讓方陳建國、寧波懷格共信股權投資合夥企業(有限合夥)(“寧波懷格”)、牛巧利、上海吉眾企業管理合夥企業(有限合夥)(“上海吉眾”)、吉芮投資管理(上海)有限公司(“吉芮投資”)簽訂《股權轉讓協議》，公司使用自有資金收購陳建國持有的吉芮醫療器械(上海)有限公司(“吉芮醫療”或“標的公司”)27.0875%股權、寧波懷格持有的吉芮醫療16.2671%股權、牛巧利持有的吉芮醫療2.6%股權、上海吉眾持有的吉芮醫療6.8493%股權及吉芮投資持有的吉芮醫療1.25%股權。此次收購完成後，吉芮醫療將成為公司控股子公司。
經協商一致，公司此次收購標的公司吉芮醫療54.0539%股權的交易價格為5027.0162萬元。
吉芮醫療擁有的知識產權情況如下： 現有二類醫療器械產品證冊型號90個，其中電動輪椅70個型號，手動輪椅20個型號； 現有2款電動輪椅、4款手動輪椅通過美國FDA認證，有8款電動輪椅、4款手動輪椅通過歐盟CE-MDR認證； 現有發明專利6項、實用新型專利51項、外觀專利30項、軟件著作權6項； 吉芮醫療及旗下控股公司現有已授權的國內註冊商標的42項，國際商標2項。
吉芮醫療是一家集研發、生產、銷售電動輪椅、老年代步車等醫療器械的高新技術企業，獲得國內註冊和海外認證的產品體系豐富，擁有完整的知識產權體系、領先的技術研發能力、高效的製造工藝流程，產品遠銷國內30多個省市及國外40多個國家和地區。
吉芮醫療是公司康復類產品的重要供應商，與公司有良好的合作基礎。公司收購其控股權補充了公司在輪椅、行動輔具等產品自主研發及生產能力的空缺，與公司優勢互補，具有良好的協同效應，有助於提升公司康復輔具類產品的整體營收規模及綜合實力，提升自有品牌及自主製造產品的比例，進一步鞏固和提升公司的核心競爭力。
吉芮醫療作為國內領先的電動輪椅生產企業，2021年新增南通新制造基地後，年設計產能已提升至25萬台(含電動輪椅和手動輪椅)，具有良好的發展前景。此次交易完成後，吉芮醫療將成為公司的控股子公司並納入合併報表範圍，將成為公司未來新的收入和利潤增長點之一。資產質量和盈利能力的提升將提高公司的核心價值，有助於實現公司股東利益特別是中小股東的利益最大化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
